Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 1;51(8):1007-1010.
doi: 10.1097/MPA.0000000000002132.

Role of Chromogranin A in the Diagnosis and Follow-up of Neuroendocrine Tumors: Real-World Experience

Mike Nguyen, Michelle Li  1 , Avraham Travers, Eva Segelov
Affiliations

Role of Chromogranin A in the Diagnosis and Follow-up of Neuroendocrine Tumors: Real-World Experience

Mike Nguyen et al. Pancreas. .

Abstract

Objective: The aim of this study was to assess the utility of serum chromogranin A (CgA) along the clinical pathway of patients with neuroendocrine tumors (NETs).

Methods: A retrospective review of medical records was conducted of patients with NET who had at least 1 measurement of CgA between January 2015 and April 2021 at a large metropolitan Australian hospital. Chromogranin A was classified as increased or decreased if there was at least a 25% change in sequential levels and was compared with disease response by anatomical or functional imaging if within 6 weeks (considered concurrent).

Results: Of 102 patients with NETs, 67 had at least 1 serum CgA level: 50 had been ordered during diagnostic workup, of which 33 were elevated (sensitivity: 66%; 95% confidence interval, 51%-79%). Of 129 CgA results concurrent with imaging, the sensitivity for detecting progressive disease was 28% (95% confidence interval, 15%-44%).

Conclusions: Our findings support previous concerns that CgA adds little value in clinical decision-making.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Öberg K. Neuroendocrine tumors and related disorders. In: Melmed S, Koenig R, Rosen C, et al., eds. Williams Textbook of Endocrinology . 14th ed. Philadelphia, PA: Elsevier; 2020:1691–1709.
    1. Leoncini E, Boffetta P, Shafir M, et al. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine . 2017;58:368–379.
    1. Pasieka JL. Carcinoid tumors. Surg Clin North Am . 2009;89:1123–1137.
    1. Hofman MS, Kong G, Neels OC, et al. High management impact of Ga-68 DOTATATE (GaTATE) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol . 2012;56:40–47.
    1. Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw . 2021;19:839–868.

LinkOut - more resources